New drug combo tested for aggressive blood cancers
NCT ID NCT03878199
Summary
This study tested a combination of two drugs, ruxolitinib and CPX-351, for people with advanced forms of certain blood cancers. The main goals were to find the safest dose of the combination and to see how well it worked to control the disease. The treatment aimed to reduce cancer cells enough so patients could potentially receive a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
OHSU
Portland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Simmons Cancer Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.